| Bioactivity | TBK1/IKKε-IN-2 is a dual TBK1 and IKKε inhibitor. | ||||||||||||
| Invitro | TBK1/IKKε-IN-2 (Cmpound #1) inhibits TBK1 biochemical function in Ulight kinase assay at 5 and 250 μM ATP concentration with IC50s of 0.6 and 2.6 nM, rsespectively. TBK1/IKKε-IN-2 inhibits IKKε biochemical function in Ulight kinase assay at 10 μM ATP with an IC50 of 3.9 nM. The IC50 of TBK1/IKKε-IN-2 in the Panc 02.13 proliferation assay is 5 μM[1]. | ||||||||||||
| Name | TBK1/IKKε-IN-2 | ||||||||||||
| CAS | 1292310-49-6 | ||||||||||||
| Formula | C26H27N5O3 | ||||||||||||
| Molar Mass | 457.52 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Muvaffak A, et al. Evaluating TBK1 as a therapeutic target in cancers with activated IRF3. Mol Cancer Res. 2014 Jul;12(7):1055-66. |